Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group
about
Bone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaOsteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate TherapiesBone resorption: an actor of dental and periodontal development?Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcomaBone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaA national portfolio of bone oncology trials-The Canadian experience in 2012.Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patientsProteomics of osteosarcoma.Advances in therapy for pediatric sarcomas.MicroRNA-128 inhibits EMT of human osteosarcoma cells by directly targeting integrin α2.Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways.Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180
P2860
Q26771376-72CC3390-326C-4AFD-8FAB-4AD01B55008AQ26782646-3EDA8862-8D75-4BBA-AFCB-EAAA8DA1C367Q28081762-25929C2A-BC2D-4BDC-BE3C-25188E09F85EQ34365891-0220EB15-6703-47F3-B334-D22C0219B170Q35894540-8D2F68E6-0B03-4868-ABF1-4C34FA884E75Q36316518-7ADF2489-DB39-4882-9B4D-11884A59ED71Q36491443-D4E9DC94-F9E9-495B-8B20-6BA00454A3C4Q36846801-DCA1F569-1FF7-44D8-A614-C3F781592A24Q38198116-8427818E-E243-40D4-83D5-F80B12901D2EQ38217354-0B1E103B-820E-4766-B51A-ED54E76D7C08Q38809325-A89B32E6-5D89-4162-946E-8755765C7452Q39032864-29F58C2F-53AF-43AE-803B-19B238CC2E8DQ41595578-2F67B060-3933-4F78-A543-AB0026DBB1D0Q42843612-B7297FF5-D6E2-44CC-9900-861D7D7E9621Q49422596-7965468A-8E53-41F0-9EFE-87303DF5CC6AQ57680380-81DEBFBD-60CA-434A-9D50-641E47BD69AD
P2860
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Feasibility and dose discovery ...... the Children's Oncology Group
@en
type
label
Feasibility and dose discovery ...... the Children's Oncology Group
@en
prefLabel
Feasibility and dose discovery ...... the Children's Oncology Group
@en
P2093
P2860
P1476
Feasibility and dose discovery ...... the Children's Oncology Group
@en
P2093
Doojduen Villaluna
James Meyer
Lars M Wagner
Mark Bernstein
Mark Krailo
Michael S Isakoff
Neyssa Marina
R Lor Randall
Robert E Goldsby
P2860
P304
P356
10.1016/J.EJCA.2013.03.018
P577
2013-05-07T00:00:00Z